Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).
Article CAS PubMed Google Scholar
Dougan, M., Luoma, A. M., Dougan, S. K. & Wucherpfennig, K. W. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 184, 1575–1588 (2021).
Article CAS PubMed PubMed Central Google Scholar
Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 8, 1069–1086 (2018).
Wherry, E. J. T cell exhaustion. Nat. Immunol. 12, 492–499 (2011).
Article CAS PubMed Google Scholar
Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767–1778 (2016).
Article CAS PubMed PubMed Central Google Scholar
Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576 (2022).
Article CAS PubMed Google Scholar
Maruhashi, T., Sugiura, D., Okazaki, I. & Okazaki, T. LAG-3: from molecular functions to clinical applications. J. Immunother. Cancer 8, e001014 (2020).
Article PubMed PubMed Central Google Scholar
Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).
Article CAS PubMed Google Scholar
Buchbinder, E. I. & Desai, A. CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39, 98–106 (2016).
Article CAS PubMed PubMed Central Google Scholar
Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).
Article CAS PubMed PubMed Central Google Scholar
Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunother. Cancer 7, 134 (2019).
Article PubMed PubMed Central Google Scholar
Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).
Molina, G. E. et al. Temporal trends and outcomes among patients admitted for immune‐related adverse events: a single‐center retrospective cohort study from 2011 to 2018. Oncologist 26, 514–522 (2021).
Article CAS PubMed PubMed Central Google Scholar
Arnaud‐Coffin, P. et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int. J. Cancer 145, 639–648 (2019).
Abu-Shawer, O. et al. Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. J. Immunother. Cancer 8, e000992 (2020).
Article PubMed PubMed Central Google Scholar
Plaçais, L. et al. Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae. Brain Commun. 3, fcab220 (2021).
Article PubMed PubMed Central Google Scholar
Dubey, D. et al. Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann. Neurol. 87, 659–669 (2020).
Rossi, S. et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J. Neurol. 270, 2975–2986 (2023).
Article CAS PubMed PubMed Central Google Scholar
Cuzzubbo, S. et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 73, 1–8 (2016).
Hyun, J.-W., Kim, K. H., Kim, S.-H. & Kim, H. J. Severe neuromuscular immune-related adverse events of immune checkpoint inhibitors at National Cancer Center in Korea. J. Cancer Res. Clin. Oncol. 149, 5583–5589 (2023).
Wang, D. Y. et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 4, 1721–1728 (2018).
Article PubMed PubMed Central Google Scholar
Farina, A. et al. Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. 5, fcad169 (2023).
Article PubMed PubMed Central Google Scholar
Kao, J. C. et al. Neurological complications associated with anti–programmed death 1 (PD-1) antibodies. JAMA Neurol. 74, 1216–1222 (2017).
Article PubMed PubMed Central Google Scholar
Farina, A., Villagrán-García, M., Vogrig, A. & Joubert, B. Central nervous system adverse events of immune checkpoint inhibitors. Curr. Opin. Neurol. 37, 345–352 (2024).
Article CAS PubMed Google Scholar
Guidon, A. C. et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J. Immunother. Cancer 9, e002890 (2021).
Article PubMed PubMed Central Google Scholar
Dubey, D. et al. Varied phenotypes and management of immune checkpoint inhibitor—a neuropathies. Neurology 93, e1093–e1103 (2019).
Article CAS PubMed Google Scholar
Marini, A. et al. Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96, 754–766 (2021).
Article CAS PubMed Google Scholar
Sechi, E. et al. Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95, e2442–e2452 (2020).
Article CAS PubMed PubMed Central Google Scholar
Ruggiero, R. et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years. Front. Immunol. 14, 1134436 (2023).
Article CAS PubMed PubMed Central Google Scholar
Amato, A. A. & Ropper, A. H. Sensory ganglionopathy. N. Engl. J. Med. 383, 1657–1662 (2020).
Chompoopong, P. et al. Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. J. Neurol. Neurosurg. Psychiatry 93, 112 (2022).
Löffel, N. B., Rossi, L. N., Mumenthaler, M., Lütschg, J. & Ludin, H.-P. The Landry–Guillain–Barré syndrome: complications, prognosis and natural history in 123 cases. J. Neurol. Sci. 33, 71–79 (1977).
Comments (0)